FOXP3 (rs 3761548) and BRAF (V600E) gene polymorphism among Egyptians with hepatocellular carcinoma

References

• Naro C, Cunliffe HE, Sette C. Editorial: insight in cancer genetics: 2022. Front Oncol. 2022;12. doi: 10.3389/fonc.2022.988310
   Web of Science ®Google Scholar
• Caruso S, O’Brien DR, Cleary SP, et al. Genetics of hepatocellular carcinoma: approaches to explore molecular diversity. Hepatology. 2021;73(S1):14–26.‏. doi: 10.1002/hep.31394
   PubMedGoogle Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491. doi: 10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.‏.
   PubMed Web of Science ®Google Scholar
• Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7(3):308–319. doi: 10.1016/j.gendis.2020.01.014
   PubMed Web of Science ®Google Scholar
• Fondevila F, Fernández-Palanca P, Méndez-Blanco C, et al. Association of FOXO3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: a systematic review with meta-analysis. Cancers (Basel). 2021;13(21):5349.‏. doi: 10.3390/cancers13215349
   Web of Science ®Google Scholar
• You D, Wang Y, Zhang Y, et al. Association of Foxp3 promoter polymorphisms with susceptibility to endometrial cancer in the Chinese Han women. Medicine. 2018;97(18):e0582. doi: 10.1097/MD.0000000000010582
   PubMed Web of Science ®Google Scholar
• Loo CS, Gatchalian J, Liang Y, et al. A genome-wide CRISPR screen reveals a role for the non-canonical nucleosome-remodeling BAF complex in Foxp3 expression and regulatory T cell function. Immunity. 2020;53(1):143–157. doi: 10.1016/j.immuni.2020.06.011
   PubMed Web of Science ®Google Scholar
• Motawi TMK, Sadik NAH, Sabry D, et al. rs62139665 polymorphism in the promoter region of EpCAM is associated with hepatitis C virus-related hepatocellular carcinoma risk in Egyptians. Front Oncol. 2022;11:754104. doi: 10.3389/fonc.2021.754104
   PubMed Web of Science ®Google Scholar
• Motawi TMK, Sadik NAH, Sabry D, et al. rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Sci Rep. 2019;9(1):6868. doi: 10.1038/s41598-019-43376-3
   PubMedGoogle Scholar
• Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–185. doi: 10.1016/j.canlet.2020.07.022
   PubMed Web of Science ®Google Scholar
• Beyzaei Z, Shojazadeh A, Geramizadeh B. The role of regulatory T cells in liver transplantation. Transpl Immunol. 2022;70:101512.‏. doi: 10.1016/j.trim.2021.101512
   PubMed Web of Science ®Google Scholar
• Malapelle U, Rossi G, Pisapia P, et al. BRAF as a positive predictive biomarker: focus on lung cancer and melanoma patients. Crit Rev Oncol Hematol. 2020;156:103118. doi: 10.1016/j.critrevonc.2020.103118
   PubMed Web of Science ®Google Scholar
• Barreno LRQ, Mello JBHD, Barros-Filho MC, et al. Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma. Braz J Otorhinolaryngol. 2022;88(4):523–528. doi: 10.1016/j.bjorl.2020.07.007
   PubMed Web of Science ®Google Scholar
• Saad AM, Abdel‐Megied AE, Elbaz RA, et al. Genetic variants of APEX1 p. Asp148Glu and XRCC1 p. Gln399Arg with the susceptibility of hepatocellular carcinoma. J med virol. 2021;93(11):6278–6291. doi: 10.1002/jmv.27217
   PubMed Web of Science ®Google Scholar
• Lopez-Martin JA, Fernández AA, Ríos-Martín JJ, et al. Frequency and clinicopathological profile associated with braf mutations in patients with advanced melanoma in Spain. Transl Oncol. 2020;13(6):100750. doi: 10.1016/j.tranon.2020.100750
   PubMed Web of Science ®Google Scholar
• Khan MA, Massey S, Ahmad I, et al. FOXO1 gene downregulation and promoter methylation exhibits significant correlation with clinical parameters in Indian breast cancer patients. Front Genet. 2022;13:842943.‏. doi: 10.3389/fgene.2022.842943
   Web of Science ®Google Scholar
• Machnicki MM, Glodkowska-Mrowka E, Lewandowski T, et al. ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with real-time PCR-based techniques. Acta Biochimica Polonica. 2013;60(1). doi: 10.18388/abp.2013_1951
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi: 10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Rashed WM, Kandeil MAM, Mahmoud MO, et al. Hepatocellular Carcinoma (HCC) in Egypt: a comprehensive overview. J Egypt Natl Canc Inst. 2020;32(1):1–11. doi: 10.1186/s43046-020-0016-x
   PubMed Web of Science ®Google Scholar
• Koulouris A, Tsagkaris C, Spyrou V, et al. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J Hepatocell Carcinoma. 2021;8:387. doi: 10.2147/JHC.S300182
   PubMed Web of Science ®Google Scholar
• Talaat RM, Seada SM, Mohamed GI, et al. Polymorphism of FOXP3 in Egyptian patients with hepatocellular carcinoma (HCC). EC Gastroenterol Dig Syst. 2018;5:97–106.
   Google Scholar
• Akgöllü E. Evaluation of forkhead box P3 gene polymorphisms in chronic HBV infection. J Gene Med. 2020;22(6):e3172.‏. doi: 10.1002/jgm.3172
   PubMed Web of Science ®Google Scholar
• Chen J, Rong X, Liu X, et al. FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma. Cancer Cell Int. 2020;20(1):1–13.‏. doi: 10.1186/s12935-020-01265-0
   PubMed Web of Science ®Google Scholar
• Motawi TMK, Sabry D, Shehata NI, et al. Impact of FOXP1 rs2687201 genetic variant on the susceptibility to HCV‐related hepatocellular carcinoma in Egyptians. J Biochem & Molecular Tox. 2022;36(3):e22965.‏. doi: 10.1002/jbt.22965
   PubMed Web of Science ®Google Scholar
• Cheng Z, Guo Y, Ming L. Functional Foxp3 polymorphisms and the susceptibility to cancer: an update meta-analysis. Medicine. 2018;97(34):e11927. doi: 10.1097/MD.0000000000011927
   PubMed Web of Science ®Google Scholar
• Chen PJ, Lin CW, Lu HJ, et al. The impact of FOXP3 polymorphisms on oral cancer progression and clinicopathological characteristics. J Cancer. 2023;14(7):1195. doi: 10.7150/jca.84470
   PubMed Web of Science ®Google Scholar
• Chen Y, Qi X, Bian C, et al. The association of FOXP3 gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysis. Biosci Rep. 2019;39(3). doi: 10.1042/BSR20181809
   Google Scholar
• Souleymane T, Thorpe DFKS, Mawuli SD, et al. KRAS and BRAF mutations in patients with hepatocellular carcinoma in Senegal. IJGG. 2022;10(1):37. doi: 10.11648/j.ijgg.20221001.16
   Google Scholar
• Śmiech M, Leszczyński P, Wardell C, et al. Oncogenic mutation BRAF V600E changes phenotypic behavior of THLE-2 liver cells through alteration of gene expression. Int J Mol Sci. 2022;23(3):1548.‏. doi: 10.3390/ijms23031548
   PubMed Web of Science ®Google Scholar
• Terrell EM, Durrant DE, Ritt DA, et al. Distinct binding preferences between Ras and Raf family members and the impact on oncogenic Ras signaling. Molecular Cell. 2019;76(6):872–884.‏. doi: 10.1016/j.molcel.2019.09.004
   PubMed Web of Science ®Google Scholar
• Guo YJ, Pan WW, Liu SB, et al. ERK/MAPK signalling pathway and tumorigenesis (review). Exp Ther Med. 2020;19:1997–2007. doi: 10.3892/etm.2020.8454
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res. 2022;28(21):4618–4628.‏. doi: 10.1158/1078-0432.CCR-21-2138
   PubMed Web of Science ®Google Scholar
• Loo E, Khalili P, Beuhler K, et al. BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry. Appl Immunohistochem Mol Morphol. 2018;26(10):709–713. doi: 10.1097/PAI.0000000000000516
   PubMedGoogle Scholar
• Tounsi-Guettiti H, Traina H, Ayed IB, et al. BRAF V600E and novel somatic mutations in thyroid cancer of Libyan patients. Asian Pac J Cancer Prev: APJCP. 2022;23(12):4029.‏. doi: 10.31557/APJCP.2022.23.12.4029
   PubMedGoogle Scholar
• Gnoni A, Licchetta A, Memeo R, et al. Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies. Medicina. 2019;55(12):754. doi: 10.3390/medicina55120754
   PubMed Web of Science ®Google Scholar
• Zhou X, Huang JM, Li TM, et al. Clinical significance and potential mechanisms of ATP binding cassette subfamily c genes in hepatocellular carcinoma. Front Genet. 2022;13:805961.‏. doi: 10.3389/fgene.2022.805961
   Web of Science ®Google Scholar
• Nansy YA, Mona A, Rania AH, et al. Clinicopathological significance of BRAF V600E mutation in Egyptian colorectal cancer patients. Med J Cairo Univ. 2020;88(June):991–997. doi: 10.21608/mjcu.2020.110833
   Google Scholar
• Sun W, Zhang Y, Liu B, et al. Gene polymorphism of MUC15, MMP14, BRAF, and COL1A1 is associated with capsule formation in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021;2021:1–8. doi: 10.1155/2021/9990305
   Web of Science ®Google Scholar
• Ezzeddini R, Somi MH, Taghikhani M, Moaddab SY, Shirazi KM, Shirmohammadi M, … & Farrokhi AS. Association of Foxp3 rs3761548 polymorphism with cytokines concentration in gastric adenocarcinoma patients. Cytokine. 2021;138:155351. doi: 10.1016/j.cyto.2020.155351
   PubMed Web of Science ®Google Scholar